Copyright
©The Author(s) 2005.
World J Gastroenterol. Sep 28, 2005; 11(36): 5685-5687
Published online Sep 28, 2005. doi: 10.3748/wjg.v11.i36.5685
Published online Sep 28, 2005. doi: 10.3748/wjg.v11.i36.5685
Table 1 Baseline characteristics of the patients
| Patient (n) | 28 |
| Male/female | 21/7 |
| Portal thrombi (+/–) | 7/21 |
| TNM classification (II/III/IV) | 5/11/12 |
| Albumin | 3.4±0.1 (g/dL) |
| Total bilirubin | 1.3±0.2 (mg/dL) |
| ALT | 48.2±6.4 (IU/L) |
| Platelet | 11.3±1.7 (×104/mL) |
| PT | 70.9±2.8 (%) |
| AFP | 7 105±2 756 (ng/mL) |
| PIVKA-II | 11 922±4 274 (U/L) |
Table 2 Evaluation of IFNα /5-FU combination therapy
| Evaluation after 1st cyclepatient n (%) | Final resultspatient n (%) | |
| CR | 1 (3.6) | |
| PR | 16 (57.1) | 5 (17.9) |
| NR | 12 (42.9) | 22 (78.6) |
- Citation: Enjoji M, Morizono S, Kotoh K, Kohjima M, Miyagi Y, Yoshimoto T, Nakamuta M. Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005; 11(36): 5685-5687
- URL: https://www.wjgnet.com/1007-9327/full/v11/i36/5685.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i36.5685